Cost-effectiveness analysis of psoriasis treatment modalities in Malaysia

Research output: Contribution to journalArticle

Abstract

Background: There is limited evidence detailing the cost-effectiveness of psoriasis treatments in the Asian region. Therefore, this study is aimed to evaluate the cost-effectiveness of 3 psoriasis treatments tailored for moderate to severe psoriasis, namely topical and phototherapy (TP), topical and systemic (TS), and topical and biologic (TB) regimens, respectively. Methods: This has been achieved by the participation of a prospective cohort involving a total of 90 moderate to severe psoriasis patients, which has been conducted at 5 public hospitals in Malaysia. The main outcome measures have been evaluated via cost and effectiveness psoriasis area severity index (PASI)-75 and/or body surface area (BSA) <5 and/or dermatology life quality index (DLQI) ≤5), estimated from the societal perspective over a 6-months duration. All costs are based on 2015’s recorded Malaysian Ringgit (RM) currency. Results: Consequently, TS has been found to be the most cost-effective treatment with the lowest cost/PASI-75/and/or BSA <5 and/or DLQI ≤5, valued at RM9034.56 (US$2582.55). This is followed by TP, which is valued at RM28 080.71 (US$8026.93) and TB, valued at RM54 287.02 (US$15 518.06). Furthermore, one-way sensitivity analysis has highlighted the cost of medication as the most sensitive parameter. Conclusion: Thus, the input from this study is helpful for policy-makers in determining the first line treatment for moderate to severe psoriasis with consideration of the costs and its effectiveness in Malaysia. This will consequently allow hospitals to justify and provide the essential resources for further research and development, as well as the adoption of better treatment options.

Original languageEnglish
Pages (from-to)394-402
Number of pages9
JournalInternational Journal of Health Policy and Management
Volume8
Issue number7
DOIs
Publication statusPublished - 1 Jul 2019

Fingerprint

Malaysia
Psoriasis
Cost-Benefit Analysis
Phototherapy
Body Surface Area
Dermatology
Costs and Cost Analysis
Therapeutics
Quality of Life
Public Hospitals
Administrative Personnel
Health Care Costs
Outcome Assessment (Health Care)
Research

Keywords

  • Biologic
  • Cost-effectiveness
  • Malaysia
  • Phototherapy
  • Psoriasis
  • Systemic

ASJC Scopus subject areas

  • Health Policy

Cite this

Cost-effectiveness analysis of psoriasis treatment modalities in Malaysia. / Azizam, Nor Azmaniza; Ismail, Aniza; Sulong, Saperi; Md Nor, Norazirah.

In: International Journal of Health Policy and Management, Vol. 8, No. 7, 01.07.2019, p. 394-402.

Research output: Contribution to journalArticle

@article{5680296b6dd840e99117fbb1cdbd9949,
title = "Cost-effectiveness analysis of psoriasis treatment modalities in Malaysia",
abstract = "Background: There is limited evidence detailing the cost-effectiveness of psoriasis treatments in the Asian region. Therefore, this study is aimed to evaluate the cost-effectiveness of 3 psoriasis treatments tailored for moderate to severe psoriasis, namely topical and phototherapy (TP), topical and systemic (TS), and topical and biologic (TB) regimens, respectively. Methods: This has been achieved by the participation of a prospective cohort involving a total of 90 moderate to severe psoriasis patients, which has been conducted at 5 public hospitals in Malaysia. The main outcome measures have been evaluated via cost and effectiveness psoriasis area severity index (PASI)-75 and/or body surface area (BSA) <5 and/or dermatology life quality index (DLQI) ≤5), estimated from the societal perspective over a 6-months duration. All costs are based on 2015’s recorded Malaysian Ringgit (RM) currency. Results: Consequently, TS has been found to be the most cost-effective treatment with the lowest cost/PASI-75/and/or BSA <5 and/or DLQI ≤5, valued at RM9034.56 (US$2582.55). This is followed by TP, which is valued at RM28 080.71 (US$8026.93) and TB, valued at RM54 287.02 (US$15 518.06). Furthermore, one-way sensitivity analysis has highlighted the cost of medication as the most sensitive parameter. Conclusion: Thus, the input from this study is helpful for policy-makers in determining the first line treatment for moderate to severe psoriasis with consideration of the costs and its effectiveness in Malaysia. This will consequently allow hospitals to justify and provide the essential resources for further research and development, as well as the adoption of better treatment options.",
keywords = "Biologic, Cost-effectiveness, Malaysia, Phototherapy, Psoriasis, Systemic",
author = "Azizam, {Nor Azmaniza} and Aniza Ismail and Saperi Sulong and {Md Nor}, Norazirah",
year = "2019",
month = "7",
day = "1",
doi = "10.15171/ijhpm.2019.17",
language = "English",
volume = "8",
pages = "394--402",
journal = "International Journal of Health Policy and Management",
issn = "2322-5939",
publisher = "Kerman University of Medical Science",
number = "7",

}

TY - JOUR

T1 - Cost-effectiveness analysis of psoriasis treatment modalities in Malaysia

AU - Azizam, Nor Azmaniza

AU - Ismail, Aniza

AU - Sulong, Saperi

AU - Md Nor, Norazirah

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Background: There is limited evidence detailing the cost-effectiveness of psoriasis treatments in the Asian region. Therefore, this study is aimed to evaluate the cost-effectiveness of 3 psoriasis treatments tailored for moderate to severe psoriasis, namely topical and phototherapy (TP), topical and systemic (TS), and topical and biologic (TB) regimens, respectively. Methods: This has been achieved by the participation of a prospective cohort involving a total of 90 moderate to severe psoriasis patients, which has been conducted at 5 public hospitals in Malaysia. The main outcome measures have been evaluated via cost and effectiveness psoriasis area severity index (PASI)-75 and/or body surface area (BSA) <5 and/or dermatology life quality index (DLQI) ≤5), estimated from the societal perspective over a 6-months duration. All costs are based on 2015’s recorded Malaysian Ringgit (RM) currency. Results: Consequently, TS has been found to be the most cost-effective treatment with the lowest cost/PASI-75/and/or BSA <5 and/or DLQI ≤5, valued at RM9034.56 (US$2582.55). This is followed by TP, which is valued at RM28 080.71 (US$8026.93) and TB, valued at RM54 287.02 (US$15 518.06). Furthermore, one-way sensitivity analysis has highlighted the cost of medication as the most sensitive parameter. Conclusion: Thus, the input from this study is helpful for policy-makers in determining the first line treatment for moderate to severe psoriasis with consideration of the costs and its effectiveness in Malaysia. This will consequently allow hospitals to justify and provide the essential resources for further research and development, as well as the adoption of better treatment options.

AB - Background: There is limited evidence detailing the cost-effectiveness of psoriasis treatments in the Asian region. Therefore, this study is aimed to evaluate the cost-effectiveness of 3 psoriasis treatments tailored for moderate to severe psoriasis, namely topical and phototherapy (TP), topical and systemic (TS), and topical and biologic (TB) regimens, respectively. Methods: This has been achieved by the participation of a prospective cohort involving a total of 90 moderate to severe psoriasis patients, which has been conducted at 5 public hospitals in Malaysia. The main outcome measures have been evaluated via cost and effectiveness psoriasis area severity index (PASI)-75 and/or body surface area (BSA) <5 and/or dermatology life quality index (DLQI) ≤5), estimated from the societal perspective over a 6-months duration. All costs are based on 2015’s recorded Malaysian Ringgit (RM) currency. Results: Consequently, TS has been found to be the most cost-effective treatment with the lowest cost/PASI-75/and/or BSA <5 and/or DLQI ≤5, valued at RM9034.56 (US$2582.55). This is followed by TP, which is valued at RM28 080.71 (US$8026.93) and TB, valued at RM54 287.02 (US$15 518.06). Furthermore, one-way sensitivity analysis has highlighted the cost of medication as the most sensitive parameter. Conclusion: Thus, the input from this study is helpful for policy-makers in determining the first line treatment for moderate to severe psoriasis with consideration of the costs and its effectiveness in Malaysia. This will consequently allow hospitals to justify and provide the essential resources for further research and development, as well as the adoption of better treatment options.

KW - Biologic

KW - Cost-effectiveness

KW - Malaysia

KW - Phototherapy

KW - Psoriasis

KW - Systemic

UR - http://www.scopus.com/inward/record.url?scp=85068937995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068937995&partnerID=8YFLogxK

U2 - 10.15171/ijhpm.2019.17

DO - 10.15171/ijhpm.2019.17

M3 - Article

AN - SCOPUS:85068937995

VL - 8

SP - 394

EP - 402

JO - International Journal of Health Policy and Management

JF - International Journal of Health Policy and Management

SN - 2322-5939

IS - 7

ER -